Maternal vaccines during the Covid-19 pandemic:A qualitative interview study with UK pregnant women.
Covid-19
Maternal health services
Pandemics
Pregnant women
Qualitative research
Vaccines
Journal
Midwifery
ISSN: 1532-3099
Titre abrégé: Midwifery
Pays: Scotland
ID NLM: 8510930
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
09
02
2021
revised:
21
05
2021
accepted:
02
06
2021
pubmed:
2
7
2021
medline:
23
7
2021
entrez:
1
7
2021
Statut:
ppublish
Résumé
There is suboptimal uptake of recommended maternal vaccines (pertussis and influenza) during pregnancy in the UK. The Covid-19 pandemic has impacted healthcare services, and potentially vaccine coverage, and brought the need for new vaccines to be tested and rolled out. To explore: i) the impact of the Covid-19 pandemic on pregnant women's access to, and attitudes towards, routine maternal vaccines and; ii) women's attitudes towards testing Covid-19 vaccines on pregnant women and their personal willingness to take part in such a trial. Qualitative interview study with pregnant women in the Bristol and surrounding area (UK). Semi-structured telephone/videoconference interviews were conducted (following a topic guide), transcribed verbatim and subjected to thematic analysis. Thirty-one pregnant women (selected for demographic range) were interviewed in April/May 2020. Participants felt the pandemic had elevated the importance of routine maternal vaccines, though women were concerned about safety management around appointment attendance. Women were wary of receiving a new Covid-19 vaccine, with most perceiving it as riskier than Covid-19 itself. It is important to maximise the safety and efficiency of maternity appointments to encourage uptake of routine maternal vaccines, and to communicate this well. For pregnant women to gain a new vaccine or participate in a vaccine trial, they need to be convinced that the risk posed by the virus is greater than any risk of receiving a new vaccine.
Sections du résumé
BACKGROUND
BACKGROUND
There is suboptimal uptake of recommended maternal vaccines (pertussis and influenza) during pregnancy in the UK. The Covid-19 pandemic has impacted healthcare services, and potentially vaccine coverage, and brought the need for new vaccines to be tested and rolled out.
OBJECTIVES
OBJECTIVE
To explore: i) the impact of the Covid-19 pandemic on pregnant women's access to, and attitudes towards, routine maternal vaccines and; ii) women's attitudes towards testing Covid-19 vaccines on pregnant women and their personal willingness to take part in such a trial.
DESIGN
METHODS
Qualitative interview study with pregnant women in the Bristol and surrounding area (UK).
METHODS
METHODS
Semi-structured telephone/videoconference interviews were conducted (following a topic guide), transcribed verbatim and subjected to thematic analysis.
RESULTS
RESULTS
Thirty-one pregnant women (selected for demographic range) were interviewed in April/May 2020. Participants felt the pandemic had elevated the importance of routine maternal vaccines, though women were concerned about safety management around appointment attendance. Women were wary of receiving a new Covid-19 vaccine, with most perceiving it as riskier than Covid-19 itself.
CONCLUSIONS
CONCLUSIONS
It is important to maximise the safety and efficiency of maternity appointments to encourage uptake of routine maternal vaccines, and to communicate this well. For pregnant women to gain a new vaccine or participate in a vaccine trial, they need to be convinced that the risk posed by the virus is greater than any risk of receiving a new vaccine.
Identifiants
pubmed: 34198208
pii: S0266-6138(21)00141-8
doi: 10.1016/j.midw.2021.103062
pmc: PMC8192261
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Pagination
103062Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
Am J Bioeth. 2016;16(2):21-3
pubmed: 26832085
Vaccine. 2014 May 30;32(26):3122-7
pubmed: 24742490
Expert Rev Vaccines. 2020 Nov;19(11):991-993
pubmed: 32940574
J Virus Erad. 2021 Jun;7(2):100044
pubmed: 34026244
BMJ. 2014 Jul 11;349:g4219
pubmed: 25015137
Lancet. 2014 Oct 25;384(9953):1521-8
pubmed: 25037990
Int J Gynaecol Obstet. 2021 Aug;154(2):291-296
pubmed: 33872386
BMC Pregnancy Childbirth. 2022 Jan 14;22(1):33
pubmed: 35030996
Clin Exp Immunol. 2020 Nov;202(2):162-192
pubmed: 32935331
Eur J Epidemiol. 2021 Feb;36(2):197-211
pubmed: 33649879
Toxicol Sci. 2011 Jul;122(1):1-6
pubmed: 21507989
Vaccines (Basel). 2020 Sep 22;8(3):
pubmed: 32972015
Am J Obstet Gynecol MFM. 2021 Mar;3(2):100295
pubmed: 33516986
Hum Vaccin Immunother. 2018 Mar 4;14(3):758-766
pubmed: 28708952
J Obstet Gynaecol Can. 2016 Oct;38(10):945-954
pubmed: 27720094
BMJ. 2020 Jun 16;369:m2392
pubmed: 32546575
Hum Vaccin Immunother. 2020 Dec 1;16(12):2932-2937
pubmed: 33175602
Int J Environ Res Public Health. 2021 Mar 24;18(7):
pubmed: 33805097
Am J Obstet Gynecol. 2021 Sep;225(3):303.e1-303.e17
pubmed: 33775692
Br J Health Psychol. 2019 Nov;24(4):739-745
pubmed: 31654471
PLoS One. 2020 Dec 28;15(12):e0244049
pubmed: 33370323
Nat Med. 2021 Jan;27(1):8
pubmed: 33442007
N Engl J Med. 2021 Jun 17;384(24):2273-2282
pubmed: 33882218
BMC Public Health. 2021 Jun 23;21(1):1202
pubmed: 34162358
Vaccine. 2015 Nov 25;33(47):6420-9
pubmed: 26320417
Nat Rev Immunol. 2020 Nov;20(11):650
pubmed: 32989290
Vaccine. 2020 Oct 14;38(44):6922-6929
pubmed: 32893036
BJOG. 2021 Apr;128(5):880-889
pubmed: 32992408
CMAJ. 2021 Apr 19;193(16):E540-E548
pubmed: 33741725
Vaccine. 2018 May 11;36(20):2751-2759
pubmed: 29661584